New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMYHealthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.78%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
59.43
1.09
+1.87%
Follow BMY
Alert me
Revenue to profit Fiscal 2025, year to Dec 31, 2025
Of every $100 of revenue, $14.64 was left as profit. What is an income statement?
| Revenue | 48.2 | 100.0% |
|---|---|---|
| Cost of revenue | −13.9 | −28.9% |
| Gross profit | 34.3 | 71.1% |
| Research & development | −10.0 | −20.6% |
| Selling, general & admin | −7.3 | −15.1% |
| Other operating costs | −7.7 | −16.0% |
| Operating income | 9.3 | 19.4% |
| Income tax | −2.3 | −4.7% |
| Net income | 7.1 | 14.6% |
Net margin (right axis)
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.4B | $20.8B | $22.6B | $26.1B | $42.5B | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| Operating income | $5.9B | $5.1B | $6.0B | $5.0B | −$6.9B | $8.1B | $7.7B | $8.4B | −$8.4B | $9.3B |
| Net income | $4.5B | $975M | $4.9B | $3.5B | −$9.0B | $7.0B | $6.3B | $8.0B | −$8.9B | $7.1B |
| Net margin (right axis) | 23.2% | 4.7% | 21.9% | 13.2% | −21.2% | 15.1% | 13.7% | 17.9% | −18.5% | 14.6% |
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
19,427.00 | 20,776.00 | 22,561.00 | 26,145.00 | 42,518.00 | 46,385.00 | 46,159.00 | 45,006.00 | 48,300.00 | 48,194.00 |
Revenue Growth |
17.31% | 6.94% | 8.59% | 15.89% | 62.62% | 9.09% | (0.49%) | (2.50%) | 7.32% | (0.22%) |
Cost of Revenue |
4,969.00 | 6,014.00 | 6,467.00 | 8,078.00 | 11,773.00 | 9,940.00 | 10,137.00 | 10,693.00 | 13,968.00 | 13,936.00 |
Gross Profit |
14,458.00 | 14,762.00 | 16,094.00 | 18,067.00 | 30,745.00 | 36,445.00 | 36,022.00 | 34,313.00 | 34,332.00 | 34,258.00 |
R&D Expenses |
5,012.00 | 6,468.00 | 6,332.00 | 6,148.00 | 10,048.00 | 10,195.00 | 9,509.00 | 9,299.00 | 11,159.00 | 9,951.00 |
SG&A Expenses |
4,979.00 | 4,751.00 | 4,551.00 | 4,871.00 | 7,661.00 | 7,690.00 | 7,814.00 | 7,772.00 | 8,414.00 | 7,267.00 |
Operating Income |
5,915.00 | 5,131.00 | 5,968.00 | 4,975.00 | (6,871.00) | 8,098.00 | 7,713.00 | 8,440.00 | (8,379.00) | 9,328.00 |
| 5,915.00 | 5,131.00 | 5,968.00 | 4,975.00 | (6,871.00) | 8,098.00 | 7,713.00 | 8,440.00 | (8,379.00) | 9,328.00 | |
Income Tax Provision |
1,408.00 | 4,156.00 | 1,021.00 | 1,515.00 | 2,124.00 | 1,084.00 | 1,368.00 | 400.00 | 554.00 | 2,272.00 |
Income after Tax |
4,507.00 | 975.00 | 4,947.00 | 3,460.00 | (8,995.00) | 7,014.00 | 6,345.00 | 8,040.00 | (8,933.00) | 7,056.00 |
Non-Controlling Interest |
50.00 | (32.00) | 27.00 | 21.00 | 20.00 | 20.00 | 18.00 | 15.00 | 15.00 | 2.00 |
Net Income Common |
4,457.00 | 1,007.00 | 4,920.00 | 3,439.00 | (9,015.00) | 6,994.00 | 6,327.00 | 8,025.00 | (8,948.00) | 7,054.00 |
EPS (Basic) |
2.67 | 0.61 | 3.03 | 2.02 | (3.99) | 3.15 | 2.97 | 3.88 | (4.41) | 3.47 |
EPS (Diluted) |
2.65 | 0.61 | 3.03 | 2.01 | (3.99) | 3.12 | 2.95 | 3.86 | (4.41) | 3.46 |
Shares (Basic, Weighted) |
1,671.00 | 1,645.00 | 1,633.00 | 1,705.00 | 2,258.00 | 2,221.00 | 2,130.00 | 2,069.00 | 2,027.00 | 2,034.00 |
Shares (Diluted, Weighted) |
1,680.00 | 1,652.00 | 1,637.00 | 1,712.00 | 2,258.00 | 2,245.00 | 2,146.00 | 2,078.00 | 2,027.00 | 2,039.00 |
Gross Margin |
74.42% | 71.05% | 71.34% | 69.10% | 72.31% | 78.57% | 78.04% | 76.24% | 71.08% | 71.08% |
EBIT Margin |
30.45% | 24.70% | 26.45% | 19.03% | (16.16%) | 17.46% | 16.71% | 18.75% | (17.35%) | 19.36% |
EBT margin |
30.45% | 24.70% | 26.45% | 19.03% | (16.16%) | 17.46% | 16.71% | 18.75% | (17.35%) | 19.36% |
Net Profit Margin |
22.94% | 4.85% | 21.81% | 13.15% | (21.20%) | 15.08% | 13.71% | 17.83% | (18.53%) | 14.64% |
Free Cash Flow Margin |
9.49% | 20.31% | 27.10% | 28.20% | 31.28% | 32.84% | 25.88% | 28.11% | 28.87% | 26.65% |
EBITDA |
6,297.00 | 5,920.00 | 6,605.00 | 6,721.00 | 3,509.00 | 18,784.00 | 17,989.00 | 18,200.00 | 1,221.00 | 13,339.00 |
EBIT |
5,915.00 | 5,131.00 | 5,968.00 | 4,975.00 | (6,871.00) | 8,098.00 | 7,713.00 | 8,440.00 | (8,379.00) | 9,328.00 |
Income from Continuous Operations |
4,507.00 | 975.00 | 4,947.00 | 3,460.00 | (8,995.00) | 7,014.00 | 6,345.00 | 8,040.00 | (8,933.00) | 7,056.00 |
Consolidated Net Income/Loss |
4,507.00 | 975.00 | 4,947.00 | 3,460.00 | (8,995.00) | 7,014.00 | 6,345.00 | 8,040.00 | (8,933.00) | 7,056.00 |
EPS (Basic, from Continuous Ops) |
2.70 | 0.59 | 3.03 | 2.03 | (3.98) | 3.16 | 2.98 | 3.89 | (4.41) | 3.47 |
EPS (Basic, Consolidated) |
2.70 | 0.59 | 3.03 | 2.03 | (3.98) | 3.16 | 2.98 | 3.89 | (4.41) | 3.47 |
EPS (Diluted, from Cont. Ops) |
2.68 | 0.59 | 3.02 | 2.02 | (3.98) | 3.12 | 2.96 | 3.87 | (4.41) | 3.46 |
Shares (Diluted, Average) |
1,680.00 | 1,652.00 | 1,637.00 | 1,712.00 | 2,258.00 | 2,245.00 | 2,146.00 | 2,078.00 | 2,027.00 | 2,039.00 |
EPS (Diluted, Consolidated) |
2.68 | 0.59 | 3.02 | 2.02 | (3.98) | 3.12 | 2.96 | 3.87 | (4.41) | 3.46 |
EBITDA Margin |
32.41% | 28.49% | 29.28% | 25.71% | 8.25% | 40.50% | 38.97% | 40.44% | 2.53% | 27.68% |
Operating Cash Flow Margin |
15.74% | 25.39% | 31.32% | 31.40% | 33.05% | 34.94% | 28.31% | 30.80% | 31.45% | 29.37% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026